The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03718520 |
|
Recruitment Status :
Recruiting
First Posted : October 24, 2018
Last Update Posted : April 17, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment |
|---|---|
| Cannabis Use Disorder PREG1 Drug Use Fetal Exposure During Pregnancy Neurodevelopmental Abnormality | Other: no intervention, this is a purely observational study |
Cannabis is the most commonly used psychoactive substance among pregnant women, with an estimated prevalence of use between 5 to 20% in in the United States. Little is known about the neurodevelopmental consequences for the fetus, particularly in the context of contemporary cannabis use patterns including high potency strains, cannabinoids and novel routes of administration. Colorado leads the nation in implementation of legalized medical and retail marijuana. Coupled with a growing pro-marijuana advocacy movement, marijuana may be perceived as "safe" to use during pregnancy. The local actions of endocannabinoids are in place in the placenta during fetal brain development and THC and its metabolites freely pass the placental barrier and the fetal blood-brain barrier. Furthermore, cannabinoid receptors appear to be more widespread in the fetal and neonatal prefrontal cortex (PFC) and the limbic areas (the amygdala and hippocampus) than in the adult brain, thus the in utero period may be a sensitive period of human brain development during which exogenous cannabinoids could permanently alter neurodevelopmental processes. Human epidemiologic studies across diverse populations have reported an emerging theme of deficiencies related to impulse control and executive functioning among offspring with in utero exposure to cannabis starting in adolescence. Only rudimentary aspects of executive function are present in infants, thus evidence of an impact during infancy and the toddler years is sparse, inconsistent and confounded by the postnatal environment (i.e., daycare, caregiver functioning). Research is needed to evaluate the proximal impact of in utero cannabis exposure on robust metrics of neonatal brain morphology and structural integrity of white matter tracts that connect to the PFC and the limbic regions before the influence of postnatal exposures become a major confounding influence.
To address this challenge, a pilot prospective pre-birth cohort study will be conducted to investigate the impact of chronic in utero cannabis exposure by enrolling 110 mother-infant pairs (50 exposed and 60 unexposed controls) for a neonate neuroimaging scan within 2 weeks after birth. Chronic in utero cannabis exposure will be quantified using ultra-high performance liquid chromatography-tandem mass spectrometry (LC-MS) of neonatal meconium. The associations between in utero cannabis exposure and neural morphological outcomes will be examined by structural MRI and diffusion tensor imaging (DTI). The central hypothesis is that in utero cannabis exposure will be associated with alterations in grey and white matter development in the prefrontal lobe and its connectivity to limbic regions.
Specific Aim 1: To determine the magnitude of the association between in utero exposure to cannabis and neonate brain morphology and structural connectivity.
Hypothesis: In utero exposure to cannabis (assessed by THC metabolites in meconium) will be associated with the following neonate brain structural outcomes: (1) Grey matter: reduced volume in the PFC and limbic regions (i.e. the amygdala, hippocampus); (2) White matter: reduced structural integrity (assessed by fractional anisotropy) of white matter tracts that connect to the PFC and the limbic regions including the uncinate fasciculus and the cingulum bundle. The associations will be independent of other maternal substance use (i.e. tobacco), postnatal feeding practices (i.e. breastfeeding), socio-demographic characteristics and maternal mental health.
| Study Type : | Observational |
| Estimated Enrollment : | 220 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity |
| Actual Study Start Date : | November 7, 2018 |
| Estimated Primary Completion Date : | July 31, 2020 |
| Estimated Study Completion Date : | July 31, 2020 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
prenatal exposed to cannabis
50 mother-infant pairs with self-reported maternal chronic cannabis use during pregnancy
|
Other: no intervention, this is a purely observational study
No intervention |
|
prenatal not-exposed to cannabis
60 mother-infant pairs with no self-reported maternal cannabis use during pregnancy
|
Other: no intervention, this is a purely observational study
No intervention |
- region specific grey matter volume (mm^2) in the PFC and limbic regions [ Time Frame: 2 weeks postnatal age ]region specific volume (mm^2)
- structural integrity measured by fractional anisotrophy of white matter tracks that connect the PFC and limbic regions [ Time Frame: 2 weeks postnatal age ]mean fractional anisotrophy
- Negative affectivity based on a subscale from the Infant Behavioral Questionnaire (Rothbart, 1981) [ Time Frame: 1 year postpartum ]Four subscales on the IBQ-R will be combined to form a negative affectivity scale including scales of Sadness, Distress to Limitations, Fear, and Falling Reactivity/Rate of Recovery from Distress.
Biospecimen Retention: Samples Without DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Gender Eligibility Description: | This study plans to enroll pregnant women. |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- pregnant women who are receiving prenatal care at the University of Colorado Hospital at Anschutz (UCH) or Denver Health Medical Center.
- maternal positive urine toxicology screen for cannabis at any clinical prenatal visit or self-report of cannabis during pregnancy at a clinical visit
- greater than ≥ 28 weeks gestation,
- aged ≥18 years,
- expecting a singleton birth,
- live in Colorado, and plan to deliver at UCH or Denver Health Medical Center .
- Inclusion criteria for unexposed controls will be identical to that of exposed cases with the exception that they cannot have a positive toxicology screen for cannabis or self-reported cannabis use during pregnancy.
Exclusion Criteria (for unexposed cases and controls):
- use of tobacco, alcohol or other drugs during pregnancy,
- serious chronic diseases (cancer, psychiatric diseases, steroid-dependent asthma, pre-existent diabetes mellitus of any kind),
- mothers who subsequently experience a fetal death or deliver a premature infant (< 37 weeks of gestation).
- Postnatal exclusions will include failure to collect meconium samples at birth, infant neurological trauma, other neurological conditions in the infant (e.g., epilepsy),
- suspicion of metal in body or other MRI contraindications in either the mother or infant.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03718520
| Contact: Tessa Crume, PhD, MSPH | 3037244452 | tessa.crume@ucdenver.edu |
| United States, Colorado | |
| University of Colorado Hospital | Recruiting |
| Aurora, Colorado, United States, 80045 | |
| Contact: Jocelyn Phipers, RN, CCRP 303-724-7807 Jocelyn.Phipers@ucdenver.edu | |
| Sub-Investigator: Jocelyn Phipers, RN, CCRP | |
| Sub-Investigator: Chistine Conageski, MD | |
| Denver Health Medical Center | Not yet recruiting |
| Denver, Colorado, United States, 80204 | |
| Contact: Beth Kingsley, CRA 303-602-7061 Elizabeth.Kingsley@dhha.org | |
| Sub-Investigator: Elaine Stickrath, MD | |
| Principal Investigator: | Tessa Crume, PhD, MSPH | University of Colorado, Colorado School of Public Health |
| Responsible Party: | University of Colorado, Denver |
| ClinicalTrials.gov Identifier: | NCT03718520 History of Changes |
| Other Study ID Numbers: |
18-0004 R21DA043833 ( U.S. NIH Grant/Contract ) |
| First Posted: | October 24, 2018 Key Record Dates |
| Last Update Posted: | April 17, 2019 |
| Last Verified: | April 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Plan Description: | A completely de-identified dataset will be created and may be shared upon PI-agreement ad development of data sharing agreements. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
cannabis fetal programming pregnancy infant neuroimaging |
|
Marijuana Abuse Substance-Related Disorders Chemically-Induced Disorders Mental Disorders |